# Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

> **NCT00761280** · PHASE3 · TERMINATED · sponsor: **Isarna Therapeutics GmbH** · enrollment: 27 (actual)

## Conditions studied

- Anaplastic Astrocytoma
- Glioblastoma

## Interventions

- **DRUG:** trabedersen
- **DRUG:** temozolomide
- **DEVICE:** Drug delivery system for administration of AP 12009
- **PROCEDURE:** Placement of Drug Delivery System
- **DRUG:** carmustine
- **DRUG:** lomustine

## Key facts

- **NCT ID:** NCT00761280
- **Lead sponsor:** Isarna Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2012-02
- **Final completion:** 2012-06
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Unable to recruit the projected patient number. All analyses are descriptive, only.
- **Last updated:** 2014-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761280, "Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00761280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*